Back to top
more

Intersect ENT, Inc. (XENT)

(Delayed Data from NSDQ)

$23.70 USD

23.70
236,159

-0.30 (-1.25%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (184 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?

Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect strength at MiSight 1-day contact lens.

What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal fourth-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.

Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.

Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing

Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.

Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes

Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.

Intersect ENT (XENT) Up 17.6% Since Last Earnings Report: Can It Continue?

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates

Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.

Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates

Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

Why Is Intersect ENT (XENT) Down 1.2% Since Last Earnings Report?

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates

Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?

Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Intersect ENT (XENT) Stock Options

Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.

Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS

This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates

Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Intersect ENT (XENT) Q1 Earnings Expected to Decline

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Intersect ENT

Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Intersect Posts Preliminary Q1 Results, Withdraws '20 View

Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.

Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.